Evidence map›Paper›PMID 31331365›Full record

ArticleBMC research notes2019

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.

Edmund T Nartey, Raymond A Tetteh, Barbara A Yankey, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens, Alexander N O Dodoo, Margaret Lartey

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04903847 (Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04903847 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2

TypeinterventionalSponsorThomas BenfieldRan2021 to 2023Enrolled126ConditionsHiv, HIV Infections, HIV Lipodystrophy, OsteoporosisArmsDolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Edmund T NarteyCentre for Tropical Clinical Pharmacology & Therapeutics, University of Ghana School of Medicine and Dentistry, P. O. Box GP 4236, Accra, Ghana. etnartey@chs.edu.gh.ORCID http://orcid.org/0000-0002-3355-4507
Raymond A TettehUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Barbara A YankeyGeorgia State University, Atlanta, GA, USA.
Aukje K Mantel-TeeuwisseUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Hubert G M LeufkensUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Alexander N O DodooCentre for Tropical Clinical Pharmacology & Therapeutics, University of Ghana School of Medicine and Dentistry, P. O. Box GP 4236, Accra, Ghana.
Margaret LarteyDepartment of Medicine, University of Ghana School of Medicine and Dentistry, P. O. Box GP 4236, Accra, Ghana.
University of Ghana · GHUtrecht University · NLGeorgia State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTenofovir disoproxil fumarate (TDF) is a nucleotide analogue recommended in international HIV treatment guidelines. Purpose of this study was to estimate the long term effects of TDF on renal profile in a cohort of HIV patients in Ghana. Three hundred (300) consecutive HIV-positive patients who initiated TDF-based antiretroviral treatment in 2008 at the Korle-Bu Teaching Hospital were sampled. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault equation at baseline and renal impairment was defined as CrCl values of 30.0-49.9 mL/min (moderate renal impairment) and < 30 mL/min (severe renal impairment) as per institutional guidelines for renal function test.

resultsMedian follow up time was 2.9 years (IQR 2.3-3.4 years). At study endpoint, 63 participants (21.0% [95% CI 6.5-26.1]) recorded CrCl rate below 50 mL/min indicating incident renal impairment, made up of 18.3% moderate renal impairment and 2.3% severe renal impairment. Factors associated with incidence of renal impairment were increasing age, decrease in creatinine clearance rate at baseline, WHO HIV stage III/IV and participants with BMI of < 18.5 kg/m

Indexed as

AdultAnti-HIV AgentsCohort StudiesFemaleGhanaHIV InfectionsHumansIncidenceKidneyKidney Function TestsMaleMiddle AgedRenal InsufficiencyTenofovirAnti-HIV AgentsTenofovirARTCreatinine clearanceHIVRenal dysfunctionTenofovir disoproxil fumarate

Identifiers

PMID31331365
PMCPMC6647254
OpenAlexW2964335390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.